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Abstract
 . The PACAP receptor PACAP I receptor, selective for PACAP and the PACAP II VIP receptor recognizing PACAP1
.  .and VIP with the same high affinity were stably expressed in Chinese Hamster Ovary CHO cells. Cell lines expressing
different receptor densities, as measured by binding saturation curves, were selected. Inositol phosphate production was
stimulated dose dependently in all the cell lines by PACAP and VIP, and the order of potency of the agonists was identical
to that of high affinity receptor occupancy. The stimulatory effect of a saturating peptide concentration was proportional to
the total receptor density. At similar receptor densities, however, the PACAP receptor mediated stimulation was higher than
the VIP receptor-mediated stimulation. Pretreatment of the cells with pertussis toxin for 8 h had no effect on receptor
densities, did not alter the PACAP stimulated inositol phosphate synthesis by the cells expressing the PACAP I receptor but
markedly inhibited the response of the cells expressing the PACAP II VIP receptor. Thus, the present results indicate that1
the two G -coupled PACAP I and PACAP II VIP receptors may stimulate IP production. The maximal stimulations 1
depended on the number of receptor expressed; the PACAP I and PACAP II VIP receptors probably activated the1
phospholipase C through G proteins of the G , and of the G rG families, respectively.q i o
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1. Introduction
Two natural forms of PACAP: PACAP-27 and the
C-terminally prolonged peptide PACAP-38 are syn-
thesized by alternative processing of a single peptide
precursor. Both PACAPs PACAP-27 and PACAP-
.38 and VIP activate two receptor classes: the PACAP
)  .Corresponding author. Fax: 32-2 555.62.30; E-mail:
probbe@ulb.ac.be
I receptors, which are selective for both PACAPs and
have a low affinity for the parent peptide VIP, and
the PACAP II receptors, which are non selective and
have a similar high affinity for VIP and both PACAPs.
The latter receptors were previously named VIP re-
w xceptors 1,2 .
Both receptor classes activate the adenylate cy-
clase. In several cells naturally expressing the selec-
w xtive PACAP I receptors 3–6 , PACAPs also stimu-
late the IP production and increase the cytoplasmic3
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calcium concentration. In contrast, in rat GH pitu-3
w xitary cells 5 that express VIP receptors, PACAP and
VIP stimulate cyclic AMP production but have a
negligible effect on inositol phosphate accumulation.
These observations suggested that the PACAP I re-
ceptor but not the PACAP II receptors are able to
stimulate both messenger pathways.
The concept that a single ligand can activate more
than one second messenger pathway is not new, but
proof that this may occur through interaction with a
single receptor was offered only recently following
the expression of recombinant receptors, in cell lines
that do not constitutively express the receptor studied
or any related receptor. It was thus demonstrated that
several recombinant G -coupled receptors can stimu-s
late not only the cyclic AMP production but also the
 w x w xphospholipase C activity dopamine D 7 , TSH 8 ,1
w x w x w x w xLH 9 , PTH 10 , calcitonin 11 , glucagon 12 ,
w x w xglucagon-like peptide-I 13 , vasopressin V2 14 ,
w xb -adrenergic receptor 14 and PACAP receptors2
w x.15,16 . In most of the systems studied, IP increases
occur at higher agonist concentrations than the cyclic
AMP increases and require a higher receptors density
w x14,17,18 . The presence of receptor reserve, common
for cyclic AMP increase, has not been demonstrated
for the stimulation of the IP cascade by these G -cou-s
pled receptors. Thus, the coupling of these receptors
to G is much more efficient than their coupling tos
 .the G protein s activating phospholipase C.
Three receptors recognizing VIP and PACAP have
w xbeen cloned 19–22 : it is now possible to test the
hypothesis that the PACAP I PACAP-preferring re-
.ceptor and PACAP II VIP receptors are indeed1
coupled to different G proteins, and that PACAP II
VIP receptors, unlike naturally expressed and trans-1
w xfected PACAP I receptors 2,15,16 , are really unable
to activate the Gqr -phospholipase C second mes-11
senger pathway.
To investigate this question, we decided to com-
pare the inositol phosphate production in cells stably
transfected with either PACAP I or PACAP II VIP1
receptors. We chose CHO cells for these experiments
because they present a rather unusual property: phos-
pholipase C can be stimulated in these cells not only
by G proteins belonging to the G family, but alsoqr11
by G proteins belonging to the G family. Sinceiro
activation of G proteins is readily abolished byiro
pertussis toxin treatment, it is easy to investigate the
ability of a single receptor to interact with the three
major G protein families in CHO cells: G activatess
the adenylate cyclase, while G and G activateiro qr11
the phospholipase C in a pertussis toxin-sensitive and
-insensitive manner, respectively.
It has been suggested that the capacity of a recep-
tor to couple to different G proteins is largely depen-
dent on the number of receptors expressed at the cell
w xsurface 14 . If this is the case, the differences be-
tween the response of cells expressing PACAP I and
PACAP II VIP receptors might be quantitative rather1
than qualitative. To test this hypothesis we compared
the ability of recombinant PACAP I and PACAP II
VIP receptors, stably expressed at different densities1
to stimulate phospholipase C activity.
We had previously observed that 125I-PACAP-38
labelled not only the same receptor population as
125I-PACAP-27 but also an additional receptor popu-
w xlation 23,24 . In a subsequent study, we synthesized
several PACAP analogues of differing lengths not
.naturally expressed and demonstrated that PACAP-
 .29 PACAP-27, Gly 28, Lys 29 amide was the
shortest peptide with the same pharmacological pro-
w xfile as PACAP-38 25 .
The comparison of the binding properties of 125I-
PACAP-27 and 125I-PACAP-29 with adenylate cy-
clase stimulation by recombinant PACAP I, PACAP
II VIP and chimeric PACAPrVIP receptors ex-1 1
pressed by CHO cells led us to suggest that 125I-
PACAP-29 but not 125I-PACAP-27 labelled all the
PACAP receptors, coupled as well as uncoupled to G
w xproteins 26 . We therefore decided to use this tracer,
rather than 125I-PACAP-27, to evaluate the total re-
ceptor densities in our different cell lines.
2. Materials and methods
2.1. Construction of the expression plasmids, trans-
fection, selection and expression in CHO cells
Expression and selection in cloned CHO cells has
w xbeen described previously 16,27,28 and is briefly
summarized below.
The DNA coding for the rat PACAP II VIP1
 .receptor and for the rat PACAP I normal short
receptor were introduced into a mammalian expres-
 .sion vector derived from pRCrRSV Invitrogen that
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contains the selectable neomycin phosphotransferase
w xgene, as detailed previously 16,27,28 . The resulting
recombinant plasmids were transfected into the CHO
w xcell line DG 44 by electroporation 27,28 . Forty
eight hours after transfection, geneticin-resistant cells
were selected, and cloned by dilution. Several clones
that expressed the PACAP I or the PACAP II VIP1
receptors respectively were selected on the basis of
PACAP stimulated adenylate cyclase activity, and the
presence of the expected mRNA, confirmed by RT-
PCR. For each recombinant receptor, up to five clones
were finally selected on the basis of the receptor
density expressed at the cell surface, as explained
below.
2.2. Cell cultures
Cells were maintained in a minimal essential
 .medium aMEMq supplemented with 10% foetal
 .calf serum FCS , 2 mM L-glutamine, 400 mgrml
geneticin at 378C in an atmosphere of 95% air-5%
CO . The subcultures for the experiments were main-2
tained without geneticin in the medium.
2.3. Determination of receptor density
The density of receptors in each of the PACAP I
and PACAP II receptor expressing cell lines was
determined by Scatchard transformation of saturation
binding curves. The tracer used was 125I-PACAP-29
w x w x26 iodinated by the iodogen technique 29 , and
purified by adsorption on a Sep-Pak Cartridge and
elution with 50% acetonitrile in 0.1% trifluoroacetic
acid. As receptor saturation could not be achieved
with the tracer, the saturation curves were obtained
by incubating a fixed amount of tracer and increasing
w xconcentrations of unlabelled PACAP-29 26 . Binding
conditions were as follows: crude membranes pre-
w xpared as described previously 27,28 were incubated
in a 50 mM Tris-maleate buffer at pH 7.8 containing
0.5 mM MgCl , 0.5% BSA and 1 mgrml bacitracin2
in the presence of 40 000 cpm of 125I-PACAP-29 and
increasing concentrations of unlabelled PACAP-29.
Membrane dilution was adjusted for each membrane
preparation so that tracer binding was proportional to
the amount of membrane protein in the assay; after a
15 min incubation at 378C the radioactivity bound to
the membranes was separated from the free radioac-
tivity by rapid filtration through glass-fiber filters
 .GFrC Whatman, Maidstone, United Kingdom pre-
soaked for 24 h in 0.1% polyethyleneimine. Four cell
lines expressing different PACAP I receptor densities
and five cell lines expressing different PACAP II
VIP receptor densities were selected.1
2.4. Measurement of accumulation of IPs
Cells were seeded in Falcon 175 cm2 culture
dishes with 40 ml of Dulbecco’s medium enriched
w3 xwith 10% FCS and 1 mCi myo- H inositolrml and
were grown for 72 h. When pertussis toxin was
tested, 100 ngrml of the toxin was added to the
culture 8 h before cell harvesting. The cells were
rinsed with Dulbecco’s medium, harvested with
trypsinrEDTA, washed twice by centrifugation and
resuspended with Dulbecco’s medium containing 15
mM LiCl then preincubated for 10 min at 378C.
Aliquots of the cell suspension were incubated for 15
min in the presence of the tested peptides. The reac-
tion was terminated by the addition of trichloroacetic
 .  .acid TCA 5% wrv, final concentration , the sam-
ples were sonicated and centrifuged. The supernatant
was collected and the pellet washed with 5% TCA.
The supernatants were combined. TCA was elimi-
nated by four extractions with diethyl ether. After
evaporation of residual ether, 100 ml of 10 mM Tris
was added to the extract and IPs produced were
separated from myo-inositol according to a simplified
Dowex chromatography procedure derived from that
w xpreviously described 16 . After elution of myo-in-
ositol, the IPs were eluted with 3 ml of 1.0 M
formate. We verified that myo-inositol was discarded
and that IP recovery was 95% when a mixture of
3 standard H-IPs including equal amounts of labelled
inositol-1-phosphate, inositol-1,4-bisphosphate and
.inositol-1,4,5-trisphosphate was subjected to the
w3 xsame procedure. At the myo- H inositol concentra-
tion used in these studies, basal IP levels varied
between 8 000 and 10 000 dpm per assay and the
duplicates were within 5% of each other.
2.5. Chemicals
 .  .  PACAP- 1–27 , PACAP- 1–29 sPACAP- 1–
. 28 29 w x.  .27 -Gly -Lys -amide 25 , PACAP- 1–38 and VIP
were synthesized by solid phase methodology. Myo-
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w3 x  .H inositol specific radioactivity: 18.3 Cirmmol
was obtained from Amersham International Bucks,
.UK .
3. Results
3.1. PACAP-27, PACAP-38 and VIP stimulated IP
production in selected CHO cell lines that expressed
PACAP I receptors and PACAP II VIP receptors1
w xWe first confirmed our previous finding 16 that
PACAP-27, PACAP-38 and VIP stimulate dose de-
pendently IP production in clone 2–10 expressing the
 .  .‘normal’ short PACAP I receptor Fig. 1, left panel .
A maximal 2.5-fold stimulation was achieved in the
presence of 1 mM PACAP-27, PACAP-29 or
PACAP-38. PACAP-27, PACAP-38 and VIP also
stimulated the IP production in CHO cells, that ex-
 .pressed a comparable 20 pmolrmg protein PACAP
 .II VIP receptor density Fig. 1, right panel . The1
three peptides were equipotent; a 1.5 fold stimulation
was observed at 1 mM peptide concentrations.
On the two clones studied, the EC values of the50
peptides were in perfect agreement with the concen-
trations required for occupancy of the high affinity
 .  .Fig. 1. Dose-response curves of PACAP-27 v , PACAP-38 ’
 .and VIP ‘ on the total IP levels after 15 min incubation of
CHO cells expressing equivalent concentrations of the PACAP I
 .  .receptor panel A or the PACAP II VIP receptor panel B1
 .receptor densities f20 pmolrmg protein . The data are ex-
pressed in fold stimulation of IP production mean of three
.experiments . The standard deviation was always below 15% of
the average value.
Fig. 2. Effect of receptor density on the total IP production
 .measured in the presence of 1 mM PACAP-27 of different
 .clones of CHO cells expressing the PACAP I receptor v or the
 .  .PACAP II VIP receptor ‘ two experiments in each clone .1
The standard deviation was always below 15% of the average
value.
receptors which are selectively labelled by 125I-
w xPACAP-27 26–28 .
3.2. Relationship between the number of receptors
expressed and the maximal response to PACAP in
˝arious transfected CHO cell lines
We compared the stimulation of IP production in
several other CHO cell lines, expressing different
densities of PACAP I or of PACAP II VIP recep-1
tors. The receptor density was measured by saturation
curves, using 125I-PACAP-29 that labelled G
w xprotein-coupled and uncoupled receptors 26 .
Scatchard plots were in all cases linear. IP production
was evaluated by complete dose-response curves of
PACAP-27, PACAP-38 and VIP. In each responsive
preparation, the EC values were identical to those50
presented in Fig. 1. The maximum IP stimulation is
plotted as a function of receptor density in Fig. 2.
The maximal inositol phosphate response to PACAP
increased with receptor density. At equal receptors
densities, the maximal response to PACAP was higher
when mediated through PACAP I receptors than
through PACAP II VIP receptors.1
3.3. Effect of pertussis toxin pretreatment on the IP
stimulation
The CHO cell lines expressing the highest PACAP
 .I receptors clone 2–10 , and PACAP II VIP recep-1
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Fig. 3. Dose-response curves of PACAP-27 on the total IP levels
after 15 min incubation of CHO cells expressing the PACAP I
 .  .receptor panel A or the PACAP II VIP receptor panel B ,1
 .  .pretreated v or not ‘ with 100 ngrml of pertussis toxin 8 h
before cell collection. Results expressed in fold stimulation of IP
 .production mean of three experiments . The standard deviation
was always below 15% of the average value.
 .tors clone 21 densities were pretreated for 8 h with
pertussis toxin before measurement of IP production.
The response of the clone expressing the PACAP I
receptor was unaffected by the treatment Fig. 3, left
.panel . The maximum response but not the peptide
sensitivity was markedly reduced in the clone ex-
pressing the highest density of PACAP II VIP recep-1
 .tor Fig. 3, right panel . Pertussis toxin pretreatment
did not significantly modify the receptors densities in
 .the two clones tested data not shown .
4. Discussion
We demonstrated in this work that, like the PACAP
w xI receptors 3–6,16 , the PACAP II VIP receptors1
are capable of stimulating the IP production in trans-
fected CHO cells.
 .Four G-protein-activated phospholipase Cb iso-
forms have been well characterized. All these isoen-
 .zymes can be activated to various extents by a
w xsubunits of the G protein family 30 , but onlyqr11
 .two of the four isoforms b and b can also be2 3
w xactivated by G proteins bg subunits 30–33 . As a
result, activation of the abundant G protein familyiro
may also result in phospholipase C activation in those
cells which express the b and b phospholipase C2 3
isoforms. The two mechanisms of phospholipase C
activation are easily discriminated by pertussis toxin,
which catalyzes ADP-ribosylation of the a subunits
of G and G , and uncouples these G proteins fromi o
their cognate receptors.
Phospholipase C stimulation by PACAP and VIP,
acting on the PACAP II VIP receptor, was markedly1
inhibited by preincubation of the cells with the toxin.
As the receptor density was not affected by the toxin,
it is likely that G or G proteins are involved in thisi o
response. In contrast, the stimulatory effect of PACAP
and – at much higher concentrations – of VIP on the
PACAP I receptor was unaffected by the pertussis
toxin pretreatment, suggesting that this receptor may
be coupled to G proteins of the G family. Thus,qr11
two receptors of the same subfamily may be coupled
to different G proteins. The observation that the
 .‘coupling efficacy’ Fig. 2 of the PACAP I receptor
to phospholipase C is higher than that of the PACAP
II VIP receptors is also compatible with that inter-1
pretation: G proteins also activate phospholipaseqr11
 .C isoenzymes b , b which are not sensitive to G1 4 iro
proteins, and phospholipase C b and b activation2 3
by the bg subunits released by G is markedlyiro
inhibited if the enzyme is phosphorylated by protein
 . w xkinase A in the presence of high cAMP levels 34 .
Similar results were obtained with the muscarinic
receptors: muscarinic agonists stimulate IP produc-3
tion through interaction with M or M receptors;2 3
but, at similar receptor densities, the M response2
 .mediated by G proteins was lower than the Miro 3
 .effect mediated by G proteins and the M re-qr11 2
sponse but not the M response was inhibited follow-3
w x w xing pertussis toxin treatment 35 , 36 and results
.not shown .
The physiological relevance of the dual coupling
of PACAP I and PACAP II VIP receptors is unclear.1
As previously observed for several other G -coupleds
 .receptors introduction , the efficiency of PACAP I
receptors coupling with G and of PACAP II VIPqr11 1
receptors coupling with G is weak, as comparediro
 .with their interaction with G . On the other hand: 1s
 .the PACAPs and VIP concentrations necessary to
achieve half maximal stimulation of the phospholi-
 .  .pase C were low in the nM range ; 2 PACAPs
stimulate the IP production and cytoplasmic calcium3
w xconcentration not only in transfected LLC-PKI 15
w xand CHO cells 16 , but also in normal pituitary
w xgonadotropes 3 , in rat gonadotrope-derived a-T3-1
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w x w xcells 4 as well in PC 12 cells 5 and in the
w x neuroblastoma cell line NB-OK-1 6 i.e. in several
cells spontaneously expressing the selective PACAP I
.  .receptor . 3 In contrast with G , G proteinsqr11 iro
 .interact with ion potassium or calcium channels,
and are not usually coupled to phospholipase C. If
VIP receptors not only interact with G proteins in1 i3
w xthe absence of GTP 37 , but also functionally acti-
vate them, this might explain why VIP does stimulate
the synthesis of NO through a pertussis toxin-sensi-
w xtive mechanism in the gastric muscle cells 38 .
It might be argued that the receptor concentrations
obtained in our transfected cells are markedly greater
than the receptor concentrations commonly observed
in normal tissues. We should like to stress at this
125point the fact that we used an unusual tracer I-
.  125PACAP-29 which in contrast with I-VIP and
125 .I-PACAP-27 does not label only the G protein-
coupled receptors but also recognizes the uncoupled
 .receptors in excess over the G proteins . In the CHO
cell lines used in this study, 125I-PACAP-27 labelled
only 11 and 27% of the PACAP II VIP and PACAP1
I receptors recognized by 125I-PACAP-29, respec-
w xtively 26 .
In conclusion, the present results suggest that the
G -coupled PACAP I and PACAP II VIP receptorss 1
stimulate IP production in transfected CHO cells. The
maximal stimulation was dependent on the number of
receptor expressed. The PACAP I receptors probably
activated the phospholipase C through a G protein of
the G family, whereas the PACAP II VIP receptorsq 1
acted through G proteins belonging to the G or Gi o
family.
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